Metabolic Parameters in Psoriatic Patients Treated With Interleukin-12/23 Blockade (Ustekinumab)

Journal of Dermatology - United States
doi 10.1111/1346-8138.14079
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Wiley

Related search

Retraction Statement: Metabolic Parameters in Psoriatic Patients Treated With Interleukin-12/23 Blockade (Ustekinumab)

Journal of Dermatology
DermatologyMedicine
2018English

399 Blockade of the IL-12/IL-23 Pathway With Ustekinumab Modulates the Composition of the Microbiome in Lesional Skin From Psoriasis Patients

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2018English

Efficacy and Safety of Ustekinumab in Patients With Psoriasis and Psoriatic Arthritis

Clinical pharmacology and therapy
2018English

SARS-CoV-2 Infection in a Psoriatic Patient Treated With IL-23 Inhibitor

Journal of the European Academy of Dermatology and Venereology
DermatologyInfectious Diseases
2020English

Effectiveness of Resuming Ustekinumab Therapy in Psoriasis Patients With Metabolic Disorders. Clinical Experience

Vestnik dermatologii i venerologii
2019English

Increased Prevalence of the Metabolic Syndrome in Patients With Psoriatic Arthritis

Metabolic Syndrome and Related Disorders
Internal MedicineEndocrinologyMetabolismDiabetes
2010English

567 Stability of PASI 90 Response in Psoriasis Patients Treated With Ixekizumab or Ustekinumab

Journal of Investigative Dermatology
BiochemistryDermatologyCell BiologyMolecular Biology
2019English

Serum Concentration of Osteopontin and Interleukin 17 in Psoriatic Patients

Advances in Clinical and Experimental Medicine
BiochemistryMedicineGeneticsMolecular Biology
2020English

AB0760 Efficacy of Ustekinumab in a Cohort of Patients Affected by Psoriatic Arthritis in Real-Life

2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy